Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs

rVSV-ΔG-SARS-CoV-2-S is a clinical stage (Phase 2) replication competent recombinant vaccine against SARS-CoV-2. To evaluate the safety profile of the vaccine, a series of non-clinical safety, immunogenicity and efficacy studies were conducted in four animal species, using multiple doses (up to 10(8...

Descripción completa

Detalles Bibliográficos
Autores principales: Madar-Balakirski, Noa, Rosner, Amir, Melamed, Sharon, Politi, Boaz, Steiner, Michal, Tamir, Hadas, Yahalom-Ronen, Yfat, Bar-David, Elad, Ben-Shmuel, Amir, Sittner, Assa, Glinert, Itai, Weiss, Shay, Bar-Haim, Erez, Cohen, Hila, Elia, Uri, Achdout, Hagit, Erez, Noam, Rotem, Shahar, Lazar, Shlomi, Nyska, Abraham, Yitzhaki, Shmuel, Beth-Din, Adi, Levy, Haim, Paran, Nir, Israely, Tomer, Marcus, Hadar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Immunotoxicology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760087/
https://www.ncbi.nlm.nih.gov/pubmed/35032184
http://dx.doi.org/10.1007/s00204-021-03214-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760087/
https://www.ncbi.nlm.nih.gov/pubmed/35032184
http://dx.doi.org/10.1007/s00204-021-03214-w

Ejemplares similares